Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023 ...

Related Keywords

United States ,Brazil ,Canada ,India ,Texas ,Rehovot ,Hamerkaz ,Israel ,Argentina ,Russia ,Australia ,America ,Israeli ,Chaime Orlev ,Brian Ritchie ,Company Generated ,Nasdaq ,Exchange Commission ,Us Securities Exchange ,Lifesci Advisors ,European Medicines Agency ,Israeli Ministry Of Health ,Globenewswire Inc ,Kamada Ltd ,Extended Agreement Term ,Significant Increase ,Rabies Immune Globulin ,Medicines Agency ,Exchange Act ,Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,